Anthropic’s 6 biggest healthcare moves in 2026 so far

Anthropic has made a series of healthcare-related moves in 2026, ranging from product launches and research efforts to policy proposals and cybersecurity initiatives. According to Becker’s, the company has been building a broader presence across providers, life sciences organizations, public health and critical infrastructure.

One of the most visible steps came on Jan. 11, when Anthropic launched Claude for Healthcare, a HIPAA-compliant version of its AI platform. The system is designed for providers, payers, life sciences organizations and patients. Anthropic said the platform includes tools for prior authorizations, claims appeals, care coordination, regulatory submissions and patient support. It also integrates with healthcare data sources such as CMS coverage databases, ICD-10 codes and provider registries. The company also expanded its life sciences offerings to support clinical trial operations and regulatory workflows.

In May, Anthropic said it would provide $200 million in grants and Claude-related support to the Gates Foundation. The partnership is focused on healthcare initiatives, including accelerating drug and vaccine development and helping governments use health data more effectively, especially in low- and middle-income countries.

On June 2, the company expanded Project Glasswing, adding 150 organizations to an initiative aimed at identifying and fixing critical software vulnerabilities. The work uses Anthropic’s unreleased Claude Mythos Preview model. Anthropic said early participants found more than 10,000 high- and critical-severity flaws, which led to the program’s expansion into healthcare, energy and communications. The company also said it plans to broaden access to its cybersecurity tools while continuing to develop safeguards against misuse of the model’s advanced cyber capabilities.

Anthropic’s June 9 model release added another healthcare angle. The company launched Claude Fable 5 and Claude Mythos 5, which it described as a new class of AI models. Anthropic said the models sped up parts of its internal drug design work by about 10 times. It also said the models showed advanced capabilities in drug discovery, protein engineering and genomics, including generating new scientific hypotheses and completing complex biology research tasks autonomously. Fable 5 is broadly available, while Mythos 5 is limited to select partners and researchers.

On June 10, Anthropic released two policy frameworks calling for stronger federal oversight of advanced AI systems. The proposals call for mandatory safety testing, independent evaluations and penalties for companies that violate safety requirements. Anthropic also pointed to cybersecurity threats to critical infrastructure, including hospitals, as a major concern and said more secure software and modernization of legacy systems are needed. In addition, the company opposed federal preemption of state AI laws unless national rules meet or exceed the standards in its proposals.

At a June 30 event in San Francisco, Eric Kauderer-Abrams, Anthropic’s life sciences head, said the company is launching an internal drug discovery program focused on neglected diseases. He said traditional pharmaceutical companies would not consider those diseases commercially attractive. The move adds another layer to Anthropic’s healthcare push in 2026, alongside its platform, partnerships, cybersecurity work and policy positions.